- Home
- NRSN
as 07-26-2024 4:00pm EST
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
| Founded: | 2017 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 17.5M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 529.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $2.33 | Next Earning Date: | 08-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NeuroSense Therapeutics Ltd. News
NRSN Breaking Stock News: Dive into NRSN Ticker-Specific Updates for Smart Investing
PR Newswire
17 days ago
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
PR Newswire
25 days ago
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
PR Newswire
a month ago
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
MT Newswires
a month ago
NeuroSense Therapeutics Receives Delisting Notice From Nasdaq
PR Newswire
a month ago
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Compare NRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRSN NeuroSense Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.